Sugi Predict

Sugi Predict / Compounds / SCHEMBL1871672

SCHEMBL1871672

SCHEMBL1871672

NN1CCCC(C(=O)O)C1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.49
▸ HSD17B10 Q99714 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ MAPT P10636 1/20 0.41
▸ NOTUM Q6P988 2/20 0.40
▸ SLC6A1 P30531 4/20 0.38
▸ TSHR P16473 3/20 0.38
▸ LMNA P02545 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ SLC6A11 P48066 1/20 0.38
▸ SLC6A13 Q9NSD5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13654356 1.00 ALDH1A1 (0.49) ALDH1A1HSD17B10SMN1; SMN2KDM4EMEN1
SCHEMBL20284513 1.00 ALDH1A1 (0.49) ALDH1A1HSD17B10SMN1; SMN2KDM4EMEN1
Hydrochloric Acid SCHEMBL25419006 0.98 ALDH1A1 (0.51) ALDH1A1HSD17B10SMN1; SMN2KDM4EMEN1
Hydrochloric Acid SCHEMBL25419008 0.98 ALDH1A1 (0.51) ALDH1A1HSD17B10SMN1; SMN2KDM4EMEN1
SCHEMBL13533754 0.86 — —
SCHEMBL13533879 0.86 — —
SCHEMBL5301962 0.86 — —
SCHEMBL13654280 0.83 HSD17B10 (0.49) ALDH1A1HSD17B10SMN1; SMN2KDM4EMEN1
SCHEMBL7995143 0.83 HSD17B10 (0.49) ALDH1A1HSD17B10SMN1; SMN2KDM4EMEN1
SCHEMBL13654279 0.83 HSD17B10 (0.49) ALDH1A1HSD17B10SMN1; SMN2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008031016-A2 HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-03-13 — — WO claimed
WO-2005122379-A9 ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY UNIV CALIFORNIA (US) 2006-03-09 — — WO claimed
WO-2005122379-A2 ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-12-22 — — WO claimed
US-20240327385-A1 SUBSTITUTED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS LIANG GUIBAI (US) 2024-10-03 — — US disclosed
CN-117843641-A NSD3 inhibitor and preparation method and application thereof 和径医药科技（上海）有限公司 2024-04-09 — — CN disclosed
CN-110563717-B Piperidine CXCR7 receptor modulators 爱杜西亚药品有限公司 2022-08-09 — — CN disclosed
CN-109563085-B Piperidine CXCR7 receptor modulators 爱杜西亚药品有限公司 2022-08-09 — — CN disclosed
EP-3555063-B1 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2020-09-16 — — EP disclosed
EP-3468984-A2 ALPHA(V)BETA(6) INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF The Regents of the University of California (US) 2019-04-17 — — EP disclosed
EP-3426700-A1 ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR The Regents of The University of California (US) 2019-01-16 — — EP disclosed
CN-108349977-A Jak inhibitor 无锡福祈制药有限公司 2018-07-31 — — CN disclosed
WO-2011079015-A1 RGD-CONTAINING CYCLIC PEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-06-30 — — WO disclosed
WO-2011060229-A1 POROUS THIN FILMS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-05-19 — — WO disclosed
WO-2009123986-A1 APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-08 — — WO disclosed
CN-101486976-A Streptomyces hygroscopicus and use thereof HANGZHOU HUADONG MEDICINE GROU (CN) 2009-07-22 — — CN disclosed
WO-2008036449-A9 CHEMICAL ANTIBODIES FOR IMMUNOTHERAPY AND IMAGING UNIV CALIFORNIA (US) 2009-02-12 — — WO disclosed
WO-2008036449-A2 CHEMICAL ANTIBODIES FOR IMMUNOTHERAPY AND IMAGING THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-03-27 — — WO disclosed
WO-2008031016-A2 HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-03-13 — — WO disclosed
WO-2005122379-A9 ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY UNIV CALIFORNIA (US) 2006-03-09 — — WO disclosed
WO-2005122379-A2 ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-12-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327385-A1 SUBSTITUTED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS REN, ACE, AGTR1 ALDH1A1 523/4885HSD17B10 1991/4885SMN1; SMN2 4097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.